'Pan-RAS molecular glue' is a safe and effective treatment for lung and pancreatic cancers
Results from the AURORAS-1 Phase I clinical trial of an anticancer drug called ERAS-0015 have shown that it is safe and has caused tumors to shrink in hard-to-treat diseases such as lung and pancreatic cancer.
The AURORAS-1 Phase I clinical trial evaluated the safety and efficacy of a drug called ERAS-0015 in treating lung and pancreatic cancers driven by mutations in the RAS gene. Conducted at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain, the study involved 148 patients and demonstrated that ERAS-0015 is safe and can cause tumors to shrink in these hard-to-treat diseases.
Dr. Judy Wang, a medical oncologist, reported that ERAS-0015, a pan-RAS molecular glue, brought proteins together at the molecular level to block tumor growth signals from multiple cancer-driving RAS mutations. The trial showed a 44% response rate in pancreatic cancer patients and a 60% response rate in lung cancer patients treated with ERAS-0015.
The drug was also well-tolerated, with few severe side effects. Further study in larger numbers of patients is necessary to confirm the safety and efficacy of ERAS-0015.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.